# Beijing Saifu Pharmaceutical Research Institute Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-saifu-pharmaceutical-research-institute-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.safeglp.com
- Total disclosed funding: $147M
- Latest round: Series D (Dec 2, 2022)
- Investors on record: 14

## About

Established in 2016 and based in Beijing, China, Beijing Saifu Pharmaceutical Research Institute Co., Ltd. operates as a CRO (Contract Research Organization) service provider that focuses on inspection and new drug development. The company cooperates with Make Research Easy, Berry Oncology and KCBIO. It has branch officses in Suzhou, Wuxi, Guan, Shenzhen, and America. Saifu has acquired international AAALAC certification, OECD GLP qualification, biosafety level 2 laboratory registration and other qualifications or certificates. In December 2024, Beijing Saifu Pharmaceutical Research Institute Co., Ltd. closed a strategic investment le by new investor State-Owned Capital Operation and Management Centre of Beijing.

Saifu Laboratories provides innovative drug research and development solutions for many fields, such as cosmetics, pesticides and medical equipment. The products of the company includes related experimental equipment, reagents and model animals, which focuses on toxicological detection and safety evaluation of drugs and new compounds. The services provided by the company include NMPA/FDA registration, drug metabolism and kinetics evaluation, biological sample testing and companion diagnostic product development, radiopharmaceutical integrated production and development technology platform, etc.

The company generates revenue by providing experimental instruments, reagents, model animals and other products and one-stop testing and new drug research and development outsourcing services.

## Funding rounds

- Series D, Dec 2, 2022, $71M — China International Capital Corporation, SDIC Venture Capital, China National Venture Capital Investment, FOF Capital, Jianxing Medical Fund, Taiping Innovation Investment Management
- Series C, Aug 19, 2021, $46M — China International Capital Corporation, T-Capital, GF Qianhe
- Series B, Dec 29, 2020 — Legend Capital, SDIC Venture Capital, Changkejin  Investment, Probe Capital
- Series B, Oct 11, 2020, $30M — Legend Capital, China Life Insurance Company, MED-FINE Capital, Probe Capital
- Series A, Sep 4, 2019 — MED-FINE Capital
- Series A, Dec 12, 2018 — Legend Capital
- Angel, Nov 25, 2016 — QF Capital

## Investors

- QF Capital (https://capitalatlas.ai/funds/qf-capital) — Angel
- Legend Capital — Series A, Series B
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A, Series B
- China Life Insurance Company — Series B
- Probe Capital — Series B
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B, Series D
- Changkejin  Investment — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C, Series D
- T-Capital — Series C
- GF Qianhe — Series C
- China National Venture Capital Investment — Series D
- FOF Capital (https://capitalatlas.ai/funds/fof-capital) — Series D
- Jianxing Medical Fund — Series D
- Taiping Innovation Investment Management — Series D